The PPI network unveiled connections involving five prioritized proteins with the targets of seven existing medications for BC, including 5 robust interactions (AKT1-TLR1, AKT1-PARK7, AKT1-MST1, AR-PARK7, and MET-MST1) (Figure 3). Here, TLR1 is linked to breast cancer.